Insmed Inc (INSM)

[headshrink3]

Wedbush analyst Greg Wade tells Dow Jones. Still, a bright light for INSM could be FDA designated Arikace as a qualified infectious disease product and granted Arikace a fast-track designation for the treatment of non- tuberculous mycobacteria lung infections. Many see that "market opportunity being much larger than the one in cystic fibrosis," Wade says.

The upside is big long term.